香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部分內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 覆核權； 及 要求覆核上市委員會根據第13.24條作出之決定 本公告由星太鏈集團有限公司（「本公司」，連同其附屬公司，統稱「本集團」）根 據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09條 及香港法例第571章證券及期貨條例第XIVA部項下之內幕消息條文（定義見上 市規則）作出。 茲提述本公司日期為二零二五年十一月十七日及二零二五年十一月二十四日 之公告，內容有關聯交所因本公司未能根據上市規則第13.24條的規定維持足 夠的運營水平之決定（「該決定」）及本公司向上市委員會提出覆核該決定之申 請（「該等公告」）。除本公告另有界定者外，本公告所用詞彙與該等公告所界定 者具有相同涵義。 – 1 – STARCOIN GROUP LIMITED 星太鏈集團有限公司 （前稱領航醫藥及生物科技有限公司） （於開曼群島註冊成立並於百慕達存續之有限公司） （股份代號：399） 上市委員會 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部分內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 更改香港主要營業地點及聯絡方式 星太鏈集團有限公司（「本公司」）董事會（「董事會」）謹此公佈，自 2026 年 1 月 19 日起，本公司的香港主要營業地點及聯絡電話更改如下﹕ 地址 ﹕ 香港中環皇后大道中5號衡怡大廈21樓 STARCOIN GROUP LIMITED 星太鏈集團有限公司 （前稱領航醫藥及生物科技有限公司） （於開曼群島註冊成立並於百慕達存續之有限公司） （股份代號：399） 香港，二零二六年一月十九日 於本公告日期，董事會包括仰融博士（主席兼執行董事）、高源興先生（執行董事）、唐榕先生 （執行董事）、齊淑娟女士（執行董事）、龍凡博士（執行董事）、伍鳴博士（執行董事）、張慎先 生（執行董事）、張羿先生（非執行董事）、陳偉君女士（獨立非執行董事）、王榮樑先生（獨立 非執行董事）、陳金中先生（獨立非執行董事）、夏廷康博士（獨立非執行董事）及孫思崢女士（獨 立非執行董事）。 請同時參閱本公 ...

致：香港交易及結算所有限公司 公司名稱: 星太鏈集團有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00399 | 說明 | 星太鏈集團 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 120,000,000,000 | HKD | | 0.01 | HKD | | 1,200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 120,000,000,000 | HKD | | 0.01 | HKD | | 1,200,000, ...

STARCOIN GROUP LIMITED The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at http://www.starcoingroup.com and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recommends you to access the Website Version of Current Corporate Communication. As a Non-registered Shareholder, if you wish to receive Corporate Communications of the Compan ...

STARCOIN GROUP LIMITED 星太鏈集團有限公司 (Formerly known as Innovative Pharmaceutical Biotech Limited 前稱領航醫藥及生物科技有限公司) (Incorporated in the Cayman Islands and continued in Bermuda with limited liability) （於開曼群島註冊成立並於百慕達存續之有限公司） (Stock Code 股份代號：399) NOTIFICATION LETTER 通知信函 31 December 2025 Yours faithfully, Starcoin Group Limited Note: Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, inc ...

Financial Performance - The Group's revenue for the financial period amounted to approximately HK$3.2 million, representing an increase of approximately 5.8% compared to HK$3.0 million in the previous financial period[11]. - The Group recorded a loss attributable to the owners of the Company of approximately HK$116.1 million, compared to a profit of HK$101.7 million in the previous financial period[11]. - Revenue from the trading of beauty and health products was approximately HK$3.2 million, reflecting a 5.8% increase from the previous financial period[12]. - For the six months ended September 30, 2025, the company reported revenue of HK$3,206,000, an increase from HK$3,029,000 in the same period of 2024, representing a growth of approximately 5.85%[85]. - The gross profit for the period was HK$447,000, compared to HK$307,000 in the previous year, indicating a significant increase of 45.6%[85]. - The company incurred a loss before tax of HK$119,304,000, a decline from a profit of HK$100,966,000 in the same period last year[85]. - The total comprehensive income for the period was a loss of HK$119,246,000, compared to a profit of HK$100,994,000 in the previous year[85]. - For the six months ended September 30, 2025, the consolidated loss for the period was HK$119,304,000, compared to a profit of HK$100,966,000 for the same period in 2024[128]. Research and Development - The Group launched its health supplement product "Pancreon PRO" in September 2025, aimed at insulin health and blood sugar management[12]. - The in-process research and development project for an oral insulin product has a net carrying value of HK$1,076 million recorded as an intangible asset[14]. - Approximately 405 patients have been enrolled in the clinical trial testing for the oral insulin product, which commenced in July 2020[20]. - The oral insulin product is expected to be launched in the market by the third quarter of 2028, with significant demand anticipated due to the growing diabetic population in China[21]. - The product is expected to be the first oral insulin drug available in the market and will be protected for a period of 5 years under current regulations in China[21]. - The Group plans to inject additional resources into the clinical trial of the in-process R&D to facilitate its development[13]. - The Group has entered into a Preliminary Partnership Agreement with Johns Hopkins University School of Medicine to collaborate on research related to diabetes and cardiovascular disease[27]. - The Group's core mission is to provide reliable health supplement solutions for the diabetic population, with several insulin-related health products planned for launch in Hong Kong[25]. Financial Position - As of September 30, 2025, the Group's bank and cash balances were approximately HK$18.1 million, up from HK$3.7 million as of March 31, 2025[38]. - Total borrowings as of September 30, 2025, were approximately HK$1,143.0 million, an increase from HK$1,049.2 million as of March 31, 2025[39]. - As of September 30, 2025, the Group's current assets to current liabilities ratio was 0.02, up from 0.01 as of March 31, 2025[42]. - The Group's gearing ratio increased to 1.07 as of September 30, 2025, compared to 0.98 as of March 31, 2025, with total liabilities of approximately HK$1,191.1 million and total assets of approximately HK$1,110.7 million[42]. - The Group's cash and cash equivalents at the end of the period amounted to approximately HK$18,071,000, with a net increase of HK$14,404,000 during the six months[98]. - The Group's bank balances and cash are significantly lower than the liabilities due, indicating potential liquidity issues[105]. - The Group's major asset, the development of an oral insulin product, is currently in Phase III clinical trials, with future cash flow dependent on successful trial outcomes and regulatory approvals[105]. Staff and Administrative Expenses - The total staff costs, including Directors' remuneration, for the Financial Period amounted to approximately HK$3.6 million, an increase from approximately HK$2.9 million in the previous Financial Period[53]. - As of September 30, 2025, the Group had 29 full-time employees, an increase from 20 as of March 31, 2025[52]. - Administrative expenses rose to HK$12,386,000 from HK$6,683,000, reflecting an increase of 85.5% year-over-year[85]. - Total short-term employment benefits for key management personnel were HK$1,874,000 for the six months ended September 30, 2025, an increase from HK$1,754,000 in the prior year[185]. Financing and Capital Structure - The Company completed the placing of 23,555,000 shares at a price of HK$0.175 per share, generating gross proceeds of approximately HK$4,122,000, with net proceeds of approximately HK$4,000,000 fully utilized for general working capital[44]. - The company issued convertible bonds worth HK$48,212,000 during the period, contributing to changes in equity[94]. - The Company is in the final stages of negotiating the extension and restructuring of Convertible Bonds due on 28 July 2025, which is expected to alleviate short-term debt pressure[110]. - The company recognized new Convertible Bonds I after substantial modification, with a liability component of approximately HK$31,709,000 and an equity component of HK$281,320,000[156]. - The maturity date of Convertible Bonds III has been extended to July 28, 2025, as per the third amendment agreed with Extrawell[169]. Risk Management and Future Outlook - The Group maintained a prudent strategy in foreign exchange risk management, balancing foreign currency assets against liabilities without using financial instruments for hedging during the Financial Period[51]. - The Company has not established a dividend policy, considering it more appropriate to determine dividend payments based on financial performance and market conditions[61]. - Significant uncertainties exist regarding the successful implementation of the Company's plans, particularly the completion of the Clinical Trial and product launch[113]. - The financial statements have been prepared on a going concern basis, assuming the Group can meet its financial obligations in the next 12 months[106]. - The Company received financial support from a substantial shareholder, confirming that repayment of approximately HK$8,190,000 will not be demanded for at least 12 months from the date of the financial statements[108].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 STARCOIN GROUP LIMITED 星太鏈集團有限公司 （前稱領航醫藥及生物科技有限公司） （於開曼群島註冊成立並於百慕達存續之有限公司） （股份代號：399） 有關解決不發表意見行動計劃 施行情況的季度最新資料 茲提述(a)星太鏈集團有限公司（前稱領航醫藥及生物科技有限公司）（「本公司」， 連同其附屬公司統稱「本集團」）截至二零二五年三月三十一日止年度的年度報 告（「年報」）；及(b)本公司日期為二零二五年九月三十日的公告，內容有關解決 不發表意見行動計劃施行情況的季度最新資料（「二零二五年九月公告」）。除 另有指明外，本公告所用詞彙與該公告所界定者具有相同涵義。 誠如年報所披露，本公司核數師已對本公司截至二零二五年三月三十一日止 年度財務報表有關持續經營事宜發表不發表意見。 誠如二零二五年九月公告所披露，本集團就計劃及措施於二零二五年七月 三十一日（即年報刊發日期）至二零二五年九月三十日 ...

Core Viewpoint - The Hong Kong stock market has shown significant gains, with several companies experiencing notable increases in their stock prices on December 19, 2023 [1][2]. Group 1: Stock Performance - Zhihui Mining (02546.HK) saw the highest increase, rising by 135.48% to a price of 10.62 [1][2]. - Huan Da Fu Holdings (01348.HK) increased by 21.21%, reaching a price of 0.24 [1][2]. - Likou Health Life (02370.HK) experienced a rise of 14.12%, with its stock priced at 0.48 [1][2]. - Ocean Group (01991.HK) rose by 14.08%, with a current price of 0.81 [1][2]. - CHI HO DEV (08423.HK) increased by 13.04%, priced at 0.0526 [1][2]. - Huameilele (08429.HK) saw an increase of 11.29%, with a stock price of 0.0697 [1][2]. - Chunli Medical (01858.HK) rose by 7.31%, reaching a price of 16.45 [1][2]. - Saint Tang Holdings (08305.HK) increased by 7.04%, with a stock price of 0.38 [1][2]. - Star Tai Chain Group (00399.HK) saw a rise of 6.38%, priced at 0.1 [1][2]. - Southern Double Short Coinbase (07311.HK) increased by 6.09%, with a current price of 13.06 [1][2].

星太链集团(00399)公布，于十月公告后，公司于2025年12月17日与Scaling Lab订立赞助研究及战略顾问 协议，以进一步实施并加强公司与约翰斯医学院的合作措施。 公告称，与全球著名医学研究机构约翰斯医学院之Scaling Lab合作是集团就实现集团成功商业化在优质 研究所作出的真正努力及承诺，并将为集团带来重大科学及战略优势。Scaling Lab在代谢生理学、糖尿 病机制以及水通道蛋白相关途径方面的专业知识为集团提供强大的科学基础，补充口服胰岛素和口服多 肽疗法的持续开发。Young博士在该协议下的顾问角色将增强集团评估新兴技术、优化研究方向及加快 非注射型糖尿病治疗创新的能力。与全球认可生物医学研究卓越的顶尖机构(如约翰斯医学院)合作，将 大幅提升集团的科学地位并支持未来的国际合作。 根据该协议，集团对所开发知识产权拥有协商许可的有利权利可创造取得口服胰岛素及药物递送系统相 关新技术的独家或优惠权利的机会。 此外，该协议设定五年研究框架，促进持续合作、知识转移及人才培养，继而可能贡献集团全球糖尿病 治疗市场的长远竞争力。该协议为集团提升研发业务可行性与可持续发展的努力。 该协议的主要条款如下 ...

STARCOIN GROUP LIMITED 星太鏈集團有限公司 （前稱領航醫藥及生物科技有限公司） （於開曼群島註冊成立並於百慕達存續之有限公司） （股份代號：399） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任 自願公告 贊助研究及戰略顧問協議 茲提述星太鏈集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）日期 為二零二五年十月十七日的公告（「十月公告」），內容有關（其中包括）與Scaling Lab就潛在機構研究訂立諒解備忘錄。Scaling Lab為J. Hunter Young博士（「Young 博士」）於約翰斯 • 霍普金斯大學醫學院（「約翰斯醫學院」）營運之實驗室。除另 行界定外，本公告所用詞彙與十月公告所界定者具有相同涵義。 董事會欣然宣佈，於十月公告後，本公司於二零二五年十二月十七日與Scaling Lab訂立贊助研究及戰略顧問協議（「該協議」），以進一步實施並加強本公司與 約翰斯醫學院之合作措施。 該協議的主要條款如下： ...